Pierre Tariot on Aducanumab Approved to Treat Alzheimer’s Disease

COMMENT This was a milestone in several respects, as aducanumab is the first novel therapy approved for Alzheimer’s in 18 years and the first drug attacking one aspect of the underlying pathobiology. This was an extremely difficult judgment to make. I take the ...

Pierre Tariot on Biogen/Eisai Halt Phase 3 Aducanumab Trials

COMMENT This is obviously disappointing news for all stakeholders. Some things that we are reflecting on include the fact that, for drugs of this type, there is the conundrum of having to have elevated brain amyloid (and thus having had AD pathology for many ...

Pierre Tariot on Closing in on a Blood Test for Alzheimer’s?

COMMENT As the authors state carefully and clearly, these findings need to be replicated, the analytic methods need to be confirmed, ROC performance in other brain diseases is needed, and validation in clinical trials of AB lowering agents is needed. That said, ...

Pierre Tariot on Not Seeing Eye to Eye: Do Lenses Accumulate Aβ?

COMMENT There appear to be major differences in the quality of the stained images between the two papers, suggesting perhaps that the reasons lie in the particular staining technique used (Bennhold's technique used by Goldstein et al. and Moncaster et al. vs ...

Current Filters

  • TYPE: Comment x
  • Commentator: Tariot, Pierre x

Remove all filters

Filter By

  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From